Leveraging Strategies for Selective Targeting of NRAS & Q61 Mutations for Cancer Treatment
- Synthetic binding proteins are powerful tools for examining the feasibility of achieving unprecedented specificity and discovering new druggable sites
- We have developed monobodies, synthetic binding proteins, that show pan-NRAS and Q61Xselective specificity profiles, and defined their structural bases
- A new protein delivery technology enables efficient and selective inhibition of RAS signaling with monobodies, expanding their utility as tool biologics and potential therapeutics